ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

🇺🇸 Investing.com (US) —
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

AI Summary

ADARx Pharmaceuticals has filed for an IPO in the US aiming for a valuation of $1.74 billion. The pharma company's public offering is a notable event in the market and investment communities.

Markets Deals Health AI & Tech ADARx Pharmaceuticals IPO US market valuation pharmaceuticals public offering

Read original source →